Mina Mawani is a practiced and dedicated not-for-profit executive. She is a resilient, collaborative leader with a bold vision to lead organizations from vision-to-strategy-to results.
Mina’s portfolio includes over 15 years of experience in non-profit, private sector, hospital, and government roles, including President and CEO of the Canadian Women’s Foundation, Chief Development Officer for CivicAction, and Chief Executive Officer of the Aga Khan Council for Canada.
Currently, Mina is the President and Chief Executive Officer of Crohn’s and Colitis Canada. She applies her passion and enthusiasm to the Crohn’s and colitis community and is deeply engaged with the issues that matter most to her constituents – finding cures and improving lives for the millions of Canadians affected by these chronic diseases.
In recognition of her remarkable achievements, involvement, and contributions to communities across Canada, Mina has received the ICCC Humanitarian of the Year award, the RBC Top 25 Canadian Immigrant Award, the Grant’s Desi Achievers Award, and was named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network.
Mina is a highly sought after speaker and respected advocate, engaging both public and private sectors, nationally and internationally. She is a loving, devoted wife and mother of two.
Day 1: Oct 6, 2020
Gain Insights into the Impact of the Increasing Use of Biosimilars for Patients and the Marketplace
Many consider that increasing the use of biosimilars is key to putting healthcare budgets on a more financially sustainable path. Understand the implications and opportunities for your business of recent policy decisions to foster a greater market share for biosimilars. Develop an action plan to:
- Prepare and support patients in the event they need to switch to a biosimilar
- Analyse the impact on your biosimilar strategy of international collaboration to increase biosimilar market share
- Adapt your Canadian market access strategies with medical and public policy guidance
Inform your strategy for biosimilars with key public policy insights
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020